Funding profile · Consumer diagnostics
adyn
One reported seed round, no Form D on file with the SEC, and no disclosed financing in five years. The capital picture is small, and most of what is known comes from press coverage rather than filings.
$2.5MSeed round announced Apr 19, 2021, co-led by Lux Capital and M13
$2.65MTotal raised across two rounds, per a data provider
0Form D notices on file with the SEC as of Sep 23, 2026
$369List price of the only product, The Birth Control Test
Data as of September 23, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Aug 2020 | Y Combinator, Summer 2020 batch | $150,000 | Y Combinator | Data provider |
| Apr 2021 | Seed, first institutional round | $2,500,000 | Co-led by Lux Capital and M13; Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Venture Group’s Pioneer Fund, Ascend.VC; angels Anne Wojcicki, Nish Bhat, Qasar Younis, Ashley Mayer | Reported |
| 2021 to 2026 | No further round reported | None found | None | Not found |
| 2019 to 2026 | Federal grants | $0 | No NIH or NSF award to this company | NIH, NSF |
What the filings show
ADYN, Inc. · no Form D located · searched Sep 23, 2026
- Registrant search
- EDGAR company search for registrants named ADYN returns two San Francisco entities, ADYNS GEORGE and Adynxx, Inc. Neither is this company.
- Full text search
- EDGAR full text search for adyn, filtered to Form D, returns 0 hits.
- Control query
- The same search run against a comparison company returns its two Form D filings, so the tool is working.
- Announced
- $2,500,000 seed, April 19, 2021
- On file
- $0
- Rule
- A Regulation D offering requires a Form D within 15 days of the first sale. An offering under Section 4(a)(2) does not.
Reading the filings
- The round left no SEC trace.Two outlets and the lead investor all put the seed at $2.5 million in April 2021. EDGAR holds nothing. That is legal, and common for an accelerator company raising outside Regulation D, but it means every number here comes from press releases and data providers rather than a filing.
- Average check, with a caveat.A data provider counts 12 investors, 8 institutional and 4 angels. Divided evenly, $2,500,000 across 12 is about $208,000 each. Two named co-leads plus a standard accelerator allocation means the real distribution is far more skewed than that.
- The capital is small against the price of the product.$2,650,000 raised in total. At a $369 list price, roughly 7,200 tests sold at full price would equal the money raised. That is the scale the business has to clear before outside capital stops being the main input.
- Five years and five months without a disclosed round.April 19, 2021 to September 23, 2026. No Series A, no bridge, no filing. The Y Combinator directory still listed the company as active with seven employees and five open roles on September 23, 2026.
- None of it is non-dilutive.No NIH or NSF award appears under this company; awards that surface on a name search belong to Adynxx, Inc., an unrelated pain drug company. The founder has since said she would tell scientist founders to pursue grants before venture money.
- Revenue cannot be checked from outside.The only operating figures published are ratios from March 2023: 94% of customers starting or switching a method, sales into 43 of 47 states, genetic clot risk flagged in 7.5% of an initial population. No unit counts, no revenue, no update since.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Regulatory | No FDA record in the openFDA device databases. Sold as a physician-ordered test run at CLIA certified labs, which are not named. | Public record |
| Price and payment | $369. HSA and FSA accepted. No insurance coverage; the company has called coverage a priority since 2022. | Company-stated |
| Geography | United States except New York, New Jersey and Rhode Island. Sold into 43 of 47 states as of March 2023. | Company-stated |
| Clinical evidence | No registered trial and no peer-reviewed publication as of September 23, 2026. | Not found |
| Competition | The founder says several entrants pivoted away from a biological testing product. A UK pharmacogenomics lab lists a contraceptive and hormone therapy test as available soon. | Company and competitor stated |
What to watch
- A first Form D, which would be the first time this company’s financing shows up in a filing rather than a press release.
- Any Series A, or a shutdown notice. Five years of silence resolves one way or the other.
- Insurance coverage, which would change the unit economics more than any round.
- A published study. Without one, the pricing rests on a claim no external party has tested.
The adyn story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- Public recordEDGAR company and full text search for ADYN, Form D
- Public recordNIH RePORTER and NSF award search
- IndependentCreating A Safer Birth Control: adyn Raises $2.5M Seed
- IndependentSeattle startup adyn raises $2.5M from 23andMe CEO and others
- Data provideradyn funding rounds and investors
- InterviewThe Bioinformatics CRO Podcast, episode 61
- InvestorInvesting in adyn: Building Science-backed Health Options for Women
- Companyadyn reports blood clot risk and sales results
- Companyadyn directory entry: batch, status, headcount, open roles
- CompetitorPGx for hormone function, contraceptives and HRT
Compiled from SEC, NIH, NSF and FDA public records and published reports as of September 23, 2026. Form D notices report offerings under Regulation D; the absence of one does not mean no money was raised, because offerings under Section 4(a)(2) require no such notice. Healthcare Venture Capital Fund holds no position in adyn. This page is not an offer to sell or a recommendation to buy any security.